Locations:
Search
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers
Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma
Key research findings to watch
Advertisement
Advertisement